Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Seres Therapeutics, Inc.
< Previous
1
2
3
Next >
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
May 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting
May 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
May 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
April 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 07, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
February 28, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
February 14, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
February 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
January 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
November 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 02, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
October 27, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
October 26, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
October 23, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
October 19, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
October 12, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
September 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
September 07, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 03, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
July 28, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.